Following the Patent Trail: From Lydac to Wellbeing

The Men Behind Wellbeing — Chapter Ten

We have established that Stephen Ray's microvesicle technology entered the patent system through Lydac Neuroscience. We have also established that Wellbeing now promotes an autologous Cell-Free Therapy built around extracellular vesicles. The question is no longer whether the two stories look similar. It is whether the documentary record can show how—or whether—they are legally connected.

Chapter Nine ended with a challenge:

Show the chain.

If Wellbeing International Foundation's Cell-Free Therapy developed from Stephen Ray's earlier microvesicle technology, there should be a history.

Scientific history.

Corporate history.

And potentially intellectual-property history.

So for this chapter, I went back to the beginning and followed the patent itself.

Not the marketing.

Not biographies.

Not testimonials.

The patent.

And what emerges is important.

Because Stephen Ray's microvesicle invention did not exist as one isolated British application.

It became an international patent family.

Yet in the records examined for this chapter, one name continues to appear as the original corporate owner:

Lydac Neuroscience Limited.

Not Wellbeing International Foundation.

And so far, I have not found a public patent record establishing a transfer of this patent family from Lydac to Wellbeing.

That does not establish that Wellbeing lacks legitimate rights to its current technology.

But it leaves the central ownership question unanswered.

The Patent Story Begins in January 2008

The earliest priority date attached to the microvesicle invention is:

4 January 2008.

The record identifies British application:

GB0800107A.

A second British priority application followed on:

17 March 2008 — GB0804932A.

Then, on 2 January 2009, the invention moved internationally through:

PCT/GB2009/000004.

That became:

WO2009087361A1 — Microvesicles.

The inventor is identified as:

Stephen Ray.

And the original assignee is:

Lydac Neuroscience Ltd. (Google Patents)

This is the foundation of the trail.

What Was Actually Invented?

The wording of the international patent is worth understanding because it allows us to compare the historical invention with what Wellbeing describes today.

The patent concerns producing microvesicles from cells.

In simplified terms, one population of cells is subjected to an inducer.

Microvesicles produced by those cells are harvested.

Those microvesicles—or material derived from them—can then be applied to another population of cells.

Importantly, the patent describes the first cell population as autologous to the second.

The specification says the invention particularly concerns immunologically matched autologous microvesicles and discusses therapeutic and cosmetic applications. (Google Patents)

That language matters.

Because Wellbeing today describes something with striking conceptual similarities.

What Does Wellbeing Describe Today?

Wellbeing's current scientific explanation of Cell-Free Therapy places extracellular vesicles at the centre of its process.

It describes them as tiny membrane-bound packages released by cells that carry proteins, RNA and other biological molecules.

Wellbeing then describes the wider secretome as including extracellular vesicles, growth factors, cytokines and signalling molecules. (Wellbeing International Foundation)

And there is another particularly important piece of evidence.

Wellbeing's own Paul Cook case study says that in November 2017, Cook met Stephen Ray and began what Wellbeing describes as a:

“unique cell-free treatment programme”

based upon extracellular vesicles derived from Cook's own cells. (Wellbeing International Foundation)

So we now have two documented descriptions.

The earlier patent:

autologous microvesicles.

The later Wellbeing account:

extracellular vesicles derived from the patient's own cells.

That is a sufficiently close scientific relationship to investigate seriously.

But it is still not proof that the processes are identical.

Microvesicles and Extracellular Vesicles Are Not Two Unrelated Worlds

Terminology is important here.

“Extracellular vesicle” is a broad term covering membrane-bound particles released from cells.

Microvesicles are generally considered one category within the wider extracellular-vesicle field.

Indeed, Wellbeing's own research library includes the well-known 2013 review:

“Extracellular Vesicles: Exosomes, Microvesicles, and Friends.” (Wellbeing International Foundation)

So it would be misleading to suggest that “microvesicles” and “extracellular vesicles” describe completely unrelated biological concepts.

But the reverse would also be misleading.

The fact that both technologies involve extracellular vesicles does not prove that modern CFT falls within the claims of Ray's 2008 invention.

That requires a claim-by-claim technical comparison.

And potentially expert patent analysis.

The Patent Went International

The PCT record shows that the invention subsequently entered multiple national or regional patent systems.

The family includes applications in:

Europe

United States

Canada

Australia

and:

New Zealand. (Google Patents)

That matters because patent ownership and patent status can differ between jurisdictions.

There is not necessarily one global patent with one global legal status.

Each national or regional right can have its own history.

So if we genuinely want to determine what survived Lydac, we have to follow the family—not simply one European record.

Europe: EP2240189B1

The European application was:

EP09700504.5A.

It ultimately became:

EP2240189B1 — Microvesicles.

The European record identifies:

Inventor: Stephen Ray

Original Assignee: Lydac Neuroscience Ltd

and currently displays:

Current Assignee: Lydac Neuroscience Ltd.

The patent was granted on:

30 December 2015. (Google Patents)

But there is another important entry.

Its present status is shown as:

Not-in-force.

And Google Patents explicitly warns that both legal-status and assignee information can be incomplete or inaccurate and should not be treated as a definitive legal conclusion. (Google Patents)

That warning prevents us making a simplistic claim that “Lydac still owns the European patent.”

Lydac no longer exists.

And the patent is recorded as not in force.

The real question is what happened before those things occurred.

The United States Trail Is Particularly Interesting

The US history adds another dimension.

A US application published in 2011 as:

US20110014251 — Microvesicles.

The applicant is identified as:

Lydac Neuroscience Limited.

The inventor is:

Stephen Ray. (Justia Patents)

But the US record doesn't end there.

Later microvesicle applications associated with Stephen Ray were published in:

2016

and:

2018.

Justia's patent index records:

US20160032322 — Microvesicles

and:

US20180112236 — Microvesicles. (Justia Patents)

The 2018 application is especially interesting because it was filed on:

21 December 2017.

Remember that date.

December 2017 Changes the Timeline

Wellbeing's own Paul Cook account says Cook met Stephen Ray in November 2017 and subsequently began a cell-free programme based on extracellular vesicles derived from his own cells. (Wellbeing International Foundation)

Then, according to the US patent index, another microvesicle application associated with Ray was filed on:

21 December 2017. (Justia Patents)

Approximately one month later.

That does not establish that the patent application covered Cook's treatment.

We should not make that leap.

Continuation applications and related filings can occur for technical patent-prosecution reasons without representing a newly invented therapy.

But the dates are sufficiently close to deserve further examination.

Because Lydac still existed.

It would not enter administration until December 2018.

So by late 2017 we appear to have three things happening within the same broad period:

Stephen Ray remained associated with the microvesicle patent family.

A further US microvesicle application was being filed.

And according to Wellbeing's own account, Ray was involved with an autologous extracellular-vesicle treatment programme.

That makes 2017 a critical year in this investigation.

Who Was the Applicant in the Later US Filings?

This is where the next layer of patent work becomes important.

A patent family can generate:

continuations;

divisionals;

continuations-in-part;

national-phase applications;

and successor applications.

Those later filings can preserve claims from an earlier invention or pursue different claim sets arising from the same original disclosure.

Therefore, simply finding Ray's name on a 2018 publication does not tell us who owned the commercial rights.

Inventor and owner are different legal concepts.

We need the complete prosecution history.

Specifically:

Who was recorded as applicant?

Who was recorded as assignee?

Were assignments filed?

Did Lydac remain the owner?

Did Ray personally obtain rights?

Did another company appear?

And:

Did any assignment occur around the period when the CFT programme was reportedly operating?

Those records could materially advance this investigation.

The Crucial Difference Between Inventor and Owner

This point deserves repeating because it is fundamental.

Stephen Ray being named as inventor does not automatically mean Stephen Ray owned the patents.

An inventor is the person credited with creating the invention.

An assignee is the person or organisation to which the legal patent rights have been assigned.

The original international and European records identify:

Stephen Ray — inventor.

Lydac Neuroscience — assignee. (Google Patents)

That distinction becomes particularly important because Ray left Lydac as a director years before the European patent was granted.

A scientist can leave a company while intellectual property previously assigned to that company remains with it.

So Ray's later involvement with Wellbeing does not, by itself, answer the ownership question.

Neither Does Andrew Chancellor's Position

The same applies to Andrew Chancellor.

Chancellor later became a director of Lydac.

Today he is associated with Wellbeing.

But a director does not personally own every asset belonging to the company he directs.

If Lydac owned patents, those patents belonged to the corporate entity unless legally transferred.

When Lydac entered administration, its assets became subject to the insolvency process.

So the fact that Chancellor later appears at Wellbeing does not create a legal bridge between the two organisations.

There would still need to be:

an assignment;

a sale;

a licence;

or some other legitimate basis for using protected intellectual property.

Have We Found an Assignment to Wellbeing?

At the time of writing:

No public patent record examined for this chapter establishes an assignment of the original WO2009087361 / EP2240189 patent family from Lydac Neuroscience to Wellbeing International Foundation.

That statement needs to be understood carefully.

It does not mean:

“Wellbeing has no rights.”

It means:

I have not yet found the documentary transfer in the public patent records reviewed.

There could be private licensing agreements.

There could be later technology.

There could be rights held through another entity.

The relevant patents may no longer be required.

Or Wellbeing may rely predominantly upon know-how rather than enforceable patent rights.

Those possibilities remain open.

Wellbeing's Website Intellectual-Property Statement Doesn't Answer This

Wellbeing's Terms of Service contain an intellectual-property section.

It says that website content—including text, graphics, logos, images and software—is the property of Wellbeing or its content suppliers. (Wellbeing International Foundation)

That's perfectly normal.

But it answers a completely different question.

Website copyright does not establish ownership of:

the CFT manufacturing process;

extracellular-vesicle technology;

patented inventions;

laboratory protocols;

or Stephen Ray's historical intellectual property.

Those are the assets we are trying to identify.

There Is Another Important Possibility: The Patent May No Longer Matter

Suppose the old patent family has expired, lapsed or otherwise ceased to provide meaningful protection.

That does not necessarily mean Wellbeing has a problem.

Quite the opposite.

It could mean the old patent is simply historical evidence of Ray's scientific development.

Modern CFT might rely upon substantially later techniques.

Or Wellbeing might rely upon proprietary know-how that isn't disclosed publicly.

That is common in biotechnology.

Sometimes a company deliberately protects manufacturing details as trade secrets rather than publishing them in patents.

But that produces another due-diligence question:

Who owns the trade secrets?

What Happens When a Scientist Is the Know-How?

This is particularly relevant in organisations built around one scientist's expertise.

Suppose the commercially valuable part of CFT isn't a patent.

Suppose it is Stephen Ray's knowledge.

A particular conditioning process.

Timing.

Concentrations.

Laboratory parameters.

Cell handling.

Purification.

Quality-control methodology.

A protocol developed through years of experimentation.

That could potentially be commercially valuable even without patent protection.

But investors should then understand how that knowledge is secured.

Is it assigned to Wellbeing?

Is Ray an employee?

A consultant?

Does his agreement assign improvements and inventions to the company?

Could he take the know-how elsewhere?

Does Wellbeing have exclusivity?

What happens if the relationship ends?

Those questions are arguably even more important when patent protection is weak or absent.

And What Exactly Is Being Developed With Investors' Money?

This brings us back to Wellbeing's current capital raise.

If investment is being used to support research and development, investors should understand who will own the resulting intellectual property.

Suppose new CFT technology is developed using investor capital.

Will Wellbeing International Foundation own it?

Will Stephen Ray?

Will a laboratory partner?

Will another company?

Will patents be filed?

Will investors' company receive exclusive rights?

These questions should be answered in investment documentation.

Because investing in research does not automatically mean the company receiving the investment will own everything that research produces.

Contracts determine that.

The Research Library Is Evidence of a Field, Not Ownership

Wellbeing currently maintains an extensive research library containing 235 papers across 11 research fields. (Wellbeing International Foundation)

It includes research into:

extracellular vesicles;

secretome biology;

manufacturing;

neurology;

ageing;

and other areas.

Wellbeing itself correctly states that these papers are independent scientific works collected for educational reference. (Wellbeing International Foundation)

That distinction is important.

Scientific literature can support the biological plausibility of a field.

It does not give Wellbeing ownership of the science described in those papers.

Commercial ownership requires something else.

Patents.

Licences.

Trade secrets.

Contracts.

Or proprietary technology.

So What Do We Actually Know About the Patent Chain?

At this stage, the documented trail looks like this:

2008

British priority applications begin.

↓

2009

PCT/GB2009/000004 filed.

Lydac Neuroscience is the applicant/assignee.

Stephen Ray is inventor.

↓

2009

WO2009087361 published.

↓

2010 onward

National and regional applications proceed in multiple jurisdictions.

↓

2015

EP2240189B1 granted in Europe.

Lydac remains recorded as assignee in the database examined.

↓

2016

Another US microvesicle publication associated with Ray appears.

↓

November 2017

Wellbeing's account places Ray in an autologous extracellular-vesicle treatment programme.

↓

December 2017

A further US microvesicle application associated with Ray is filed.

↓

December 2018

Lydac enters administration.

↓

2019

Lydac enters liquidation.

↓

2025

Lydac is dissolved.

↓

Today

Wellbeing promotes Cell-Free Therapy involving autologous extracellular vesicles.

What remains missing from that sequence is:

the documented ownership bridge.

There Are Four Possible Explanations

At this stage, I see four broad possibilities.

First: Wellbeing or a connected entity legitimately acquired or licensed relevant Lydac intellectual property, but the documentation is not apparent in the public records reviewed.

Second: the original patents became irrelevant or ceased to provide meaningful protection, while Ray continued developing later technology that eventually became CFT.

Third: modern CFT depends primarily upon proprietary know-how, protocols and manufacturing methods rather than the historical patents.

Fourth: another company or entity sits somewhere between Lydac and Wellbeing and holds relevant rights.

There may also be combinations of these possibilities.

The next stage is determining which is correct.

What Would Resolve This Immediately?

Documentation.

Specifically:

the assignment history for the entire patent family;

the USPTO assignment records for the US applications;

the European Patent Register ownership history;

the Canadian, Australian and New Zealand ownership records;

Lydac's administrator and liquidator asset-sale records;

and:

Wellbeing's intellectual-property and licensing schedule.

Put those documents together and much of the uncertainty disappears.

Questions for Wellbeing

I would therefore invite Wellbeing International Foundation to answer the following:

Does CFT practise any claims originally disclosed in WO2009087361 or its national patent family?

Does Wellbeing own any member of that patent family?

Has Wellbeing ever licensed any member of that family?

Did Wellbeing or any connected organisation acquire intellectual property from Lydac Neuroscience?

Who owned the technology used in the Paul Cook programme described by Wellbeing in 2017?

What patents currently protect Cell-Free Therapy?

If CFT is not patent protected, what proprietary rights prevent competitors reproducing the process?

Who legally owns those rights?

And which entity will own new intellectual property produced using the capital currently being raised?

These are answerable questions.

What We Are Not Alleging

For clarity:

I have not established that Wellbeing infringes a patent.

I have not established that Wellbeing is using Lydac intellectual property without permission.

I have not established that Chancellor or Ray improperly transferred an asset.

I have not established that Lydac's creditors were deprived of intellectual property.

And I have not established that Wellbeing's CFT is identical to the invention described in WO2009087361.

Those conclusions would require substantially more evidence.

What we have established is something narrower—but important:

There is a documented historical patent family involving Stephen Ray, autologous microvesicles and Lydac Neuroscience, while Wellbeing today promotes an autologous extracellular-vesicle therapy involving the same scientist.

The legal relationship between those two technologies remains unresolved.

Conclusion: The Patent Exists. The Bridge Doesn't—Yet.

When this investigation began, one question was whether Stephen Ray really had an intellectual-property history in this field.

That question has been answered.

He does.

The patent trail reaches back to 2008.

It became international.

It involved autologous microvesicles.

And Lydac Neuroscience was the corporate assignee appearing in the foundational records. (Google Patents)

We also know that Wellbeing now promotes an autologous treatment involving extracellular vesicles and identifies Ray as a central scientific figure. (Wellbeing International Foundation)

What we still don't have is the piece between them.

Who owned the technology after Lydac?

Perhaps the answer is that nobody needed to own the old patent because the technology moved beyond it.

Perhaps Wellbeing owns later intellectual property.

Perhaps it has licences.

Perhaps the competitive asset is confidential know-how.

Perhaps another corporate entity holds the rights.

But for an organisation raising investment around regenerative biotechnology, that distinction matters enormously.

Because investors are not investing in the existence of extracellular-vesicle science.

That science belongs to an entire international research field.

They are investing in whatever Wellbeing uniquely controls within that field.

And until that proprietary asset is identified, one of the most basic investment questions remains unanswered:

What exactly does Wellbeing own that somebody else cannot legally or practically reproduce?

That is where we go next.

Next: Chapter Eleven — What Exactly Are Investors Buying?

Wellbeing is raising capital to fund research and international expansion. Chapter Eleven leaves the historical patents behind temporarily and examines the investment proposition itself: which legal entity receives the money, what assets sit inside it, what investors receive in return, how the organisation is valued, and whether the intellectual property at the centre of the scientific story actually belongs to the company investors are being asked to finance.